



April 2023 Pharmacy & Therapeutics Committee Decisions

UCare’s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare formularies (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval.

Key:

Medicare: UCare Medicare, UCare Medicare with Fairview and North Memorial, UCare Group Medicare, EssentiaCare, Minnesota Senior Health Options (MSHO) & Connect + Medicare

Medicaid: PMAP, MnCare, MSC+ & Connect

Exchange: UCare Individual and Family Plans

F: Formulary

NF: Non-formulary

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

New Drug Review			
Drug	Indication	Formulary Coverage	Effective Date
Lunsumio 1mg/ml, (mosunetuzumab-axgb) Protected Class	treatment of relapsed or refractory follicular lymphoma in adults after two or more lines of systemic therapy	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	06/01/2023
Rebyota Rectal Suspension (fecal microbiota, live-jslm)	prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent CDI	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Elahere (mirvetuximab soravtansine-gynx) PROTECTED CLASS	treatment of FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have received one to three prior systemic treatment regimens.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A
Leqembi (lecanemab-irmb)	Leqembi is indicated for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease (collectively known as early Alzheimer's disease) with confirmed presence of amyloid pathology in the brain.	Medicare: Non-Formulary Medicaid: Non-Formulary Exchange: Non-Formulary	N/A

April 2023 Pharmacy & Therapeutics Committee Decisions

Briumvi (ublituximab-xiiv)	treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	06/01/2023
Krazati (adagrasib)	is indicated for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults, as determined by an FDA-approved test, in those who have received at least one prior systemic therapy	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	06/01/2023
Rezlidhia (olutasidenib)	indicated for the treatment of adults who have acute myeloid leukemia (AML) that has returned or become unresponsive to previous therapy (r/rAML). Patients also must test positive for mutations in isocitrate dehydrogenase-1 (IDH1) enzymes.	Medicare: Formulary w/ PA Medicaid: Formulary w/ PA Exchange: Formulary w/ PA	06/01/2023
Sunlenca (lenacapavir) Protected Class	in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations	Medicare: Formulary w/ PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	06/01/2023
Tzield (teplizumab-mxwv)	indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients ≥ 8 years of age with Stage 2 type 1 diabetes	Medicare: Formulary w/PA Medicaid: Formulary w/PA Exchange: Formulary w/PA	06/01/2023

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 05/1/2023.

New Indications Review

April 2023 Pharmacy & Therapeutics Committee Decisions

Drug	Current formulary status	Recommendation
Adacel – TDaP vaccine approved for 3 rd trimester	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Brukinsa – chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults	Medicare - F, Medicaid - F, HIX - F	Medicare - F, Medicaid - F, HIX - F
Tukysa –with trastuzumab for tx of RAS wild-type, HER2+ unresectable or metastatic colorectal cancer	Medicare – F, Medicaid – F, HIX - F	Medicare – F, Medicaid – F, HIX - F
Revatio – pediatric pts PAH WHO grp1	Medicare - NF, Medicaid - F, HIX - NF	Medicare - NF, Medicaid - F, HIX - NF
Takhzyro – ped pts 2-12 prophylaxis of HAE	Medicare – NF, Medicaid – NP, HIX - NF	Medicare – NF, Medicaid – NP, HIX - NF
Cibinqo – ped pts 12-17 mod-severe atopic dermatitis	Medicare – NF, Medicaid – NP, HIX - F	Medicare – NF, Medicaid – NP, HIX - F
Kevzara – polymyalgia rheumatica	Medicare – NF, Medicaid – NP, HIX -NF	Medicare – NF, Medicaid – NP, HIX -NF
Verzenio – remove Ki-67 score requirement (Breast ca)	Medicare – F, Medicaid – F, HIX - F	Medicare – F, Medicaid – F, HIX - F
Mekinist and Tafinlar – ped pts >1 with low-grade glioma w/ BRAF V600E mutation	Medicare – F, Medicaid – F, HIX - F	Medicare – F, Medicaid – F, HIX - F
Amjevita – hidradenitis suppurativa	Medicare – F, Medicaid – F, HIX - F	Medicare – F, Medicaid – F, HIX - F
Keytruda – single agent adjuvant treatment following resection and	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF

April 2023 Pharmacy & Therapeutics Committee Decisions

platinum-based chemo for NSCLC		
Trodelvy – secondary tx of unresectable locally advanced or metastatic HR+ HER2- breast cancer	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Eylea – retinopathy of prematurity	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Jemperli – qualifier added “not candidates for curative surgery or radiation”	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Opdivo – ped pts 12-17 unresectable or metastatic melanoma	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Yervoy – ped pts 12-17 unresectable or metastatic melanoma	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Odactra – expand age to 12-17 for house dust mite immunotherapy	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Enjamo – tx hemolysis in adults with cold agglutinin disease	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Livmarli – ped pts 3mo-1yr cholestatic pruritus in Alagille syndrome	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF
Cyltezo – hidradenitis suppurativa	Medicare – NF, Medicaid – NF, HIX - NF	Medicare – NF, Medicaid – NF, HIX - NF

New Generics Review

Drug	Current formulary status	Recommendation
Topiramate ER (Trokendi XR)	Medicare: NF, Medicaid: NP , HIX: NF	Medicare: NF, Medicaid: NF , HIX: NF
Tafluprost (Zioptan)	Medicare: NF, Medicaid: NP , HIX: F	Medicare: F, Medicaid: NF , HIX: F
Dexlansoprazole DR (Dexilant)	Medicare: NF, Medicaid: NP , HIX: NF	Medicare: NF, Medicaid: NF , HIX: NF

April 2023 Pharmacy & Therapeutics Committee Decisions

Tasimelteon (Hetlioz)	Medicare: F, Medicaid: NP , HIX: F	Medicare: F, Medicaid: NF , HIX: F
Lurasidone (Latuda)	Medicare: F, Medicaid: P , HIX: F	Medicare: F, Medicaid: F , HIX: F
Bendamustine (Treanda)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: NF, Medicaid: NF, HIX: NF
Pirfenidone (Esbriet)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: NF, Medicaid: NF, HIX: NF
Lubiprostone (Amitiza)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: F , Medicaid: F , HIX: F
Dichlorphenamide (Keveyis)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: NF, Medicaid: NF, HIX: NF
Brimonidine (Mirvaso)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: NF, Medicaid: NF, HIX: NF
Diclofenac Potassium (Cambia)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: NF, Medicaid: NF, HIX: NF
Ezetimibe-Atorvastatin (Liptruzet)	Medicare: NF, Medicaid: NF, HIX: NF	Medicare: NF, Medicaid: NF, HIX: NF

Miscellaneous Previously Reviewed Items

Drug	Rationale/Alternative	Recommendation
Vivimusta (bendamustine)	Vivimusta (bendamustine)	NF all lines of business
Tempo refill/smart/welcome	Medical device attaches to tempo insulin pens (NF)	NF all lines of business
Stimufend (pegfilgrastim)	Neulasta/Onpro, Udenyca, Ziextenzo	NF all lines of business
Minocycline ER (minocycline)	Minocycline IR Fingolimod, Gilenya	NF all lines of business
Tascenso ODT (fingolimod) Modafinil, armodafinil, Sunosi	Fingolimod, Gilenya	NF all lines of business
Sodium oxybate (generic Xyrem)	Modafinil, armodafinil, Sunosi	Medicare: F Medicaid: NF

**April 2023 Pharmacy & Therapeutics
Committee Decisions**

	HIX: NF
--	---------

Additional Items Reviewed

Item	Action
New Medical Drug Policies (effective 06/15/2023)	<ul style="list-style-type: none">• Lamzede• Zynyz• Syfovre